董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Alain Munoz | 男 | Director | 75 | 未披露 | 未持股 | 2022-03-30 |
| Rosemary Crane | 女 | Vice chairman | 65 | 未披露 | 未持股 | 2022-03-30 |
| Catherine Moukheibir | 女 | Director | 65 | 未披露 | 未持股 | 2022-03-30 |
| Michael J. Owen | 男 | Director | 74 | 未披露 | 未持股 | 2022-03-30 |
| Hanne Heidenheim Bak | 女 | Director | 71 | 未披露 | 未持股 | 2022-03-30 |
| Rasmus Just | 女 | Director | 48 | 未披露 | 未持股 | 2022-03-30 |
| Jens Peter Stenvang | 男 | Director | 70 | 未披露 | 未持股 | 2022-03-30 |
| Martin Nicklasson | 男 | Chairman | 70 | 未披露 | 未持股 | 2022-03-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Mats Blom | 男 | Executive Vice President and Chief Financial Officer | 60 | 未披露 | 未持股 | 2022-03-30 |
| Adam Steensberg | 男 | Chief Executive Officer | 50 | 未披露 | 未持股 | 2022-03-30 |
| Andrew Parker | -- | Executive Vice President, Chief Science Officer | 59 | 未披露 | 未持股 | 2022-03-30 |
董事简历
中英对照 | 中文 | 英文- Alain Munoz
-
Alain Munoz担任董事：Munoz博士从2007年12月开始担任我司董事。他是制药行业的独立管理咨询师，并担任巴黎Kurma Biofund的风险合伙人。从1990年到2000年，Munoz博士担任过Fournier Group的多个管理职位，包括制药部门的高级副总裁。他从赛诺菲研究公司（Sanofi Research）加入Fournier，他在该公司最初开始担任心血管与抗血栓产品业务部的总监，之后担任国际开发部的副总裁。Munoz博士在法国蒙比利亚大学医院（University Hospital of Montpellier）获得心脏学与麻醉学资格。他担任Valneva SA, Umecrine Mood AB、 Hybrigenics S.A.与Zealand Pharma A/S的董事。他被Idinvest提名为我司董事。
Alain Munoz has been a member of our Board of Directors since March 2018 and previously served on our Board of Directors between 2007 and 2015. Mr. Munoz is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry. From 1990 to 2000 Dr. Munoz worked with the Fournier Group, as Research and Development Director and then Senior Vice President of the Pharmaceutical Division. He joined Fournier from Sanofi Research, where he started as Director in the cardiovascular and anti-thrombotic products department and then as Vice President international development. Dr. Munoz is qualified in cardiology and anesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. He has been a member of the Scientific Committee of the French drug agency. He is advisor to Kurma partners and serves on the Board of Valneva SA VLA.PA, Hybrigenics S.A. (ALHYG.PA) and Zealand Pharma A/S. (ZEAL.CO). - Alain Munoz担任董事：Munoz博士从2007年12月开始担任我司董事。他是制药行业的独立管理咨询师，并担任巴黎Kurma Biofund的风险合伙人。从1990年到2000年，Munoz博士担任过Fournier Group的多个管理职位，包括制药部门的高级副总裁。他从赛诺菲研究公司（Sanofi Research）加入Fournier，他在该公司最初开始担任心血管与抗血栓产品业务部的总监，之后担任国际开发部的副总裁。Munoz博士在法国蒙比利亚大学医院（University Hospital of Montpellier）获得心脏学与麻醉学资格。他担任Valneva SA, Umecrine Mood AB、 Hybrigenics S.A.与Zealand Pharma A/S的董事。他被Idinvest提名为我司董事。
- Alain Munoz has been a member of our Board of Directors since March 2018 and previously served on our Board of Directors between 2007 and 2015. Mr. Munoz is an entrepreneur and independent management consultant in the pharmaceutical and biotechnology industry. From 1990 to 2000 Dr. Munoz worked with the Fournier Group, as Research and Development Director and then Senior Vice President of the Pharmaceutical Division. He joined Fournier from Sanofi Research, where he started as Director in the cardiovascular and anti-thrombotic products department and then as Vice President international development. Dr. Munoz is qualified in cardiology and anesthesiology from the University Hospital of Montpellier, France where he was head of the clinical cardiology department. He has been a member of the Scientific Committee of the French drug agency. He is advisor to Kurma partners and serves on the Board of Valneva SA VLA.PA, Hybrigenics S.A. (ALHYG.PA) and Zealand Pharma A/S. (ZEAL.CO).
- Rosemary Crane
-
Rosemary Crane于2015年4月当选为董事会成员，此后一直担任副主席兼审计委员会成员。她是根据丹麦公司治理建议的独立董事会成员。Crane女士曾于2013年至2014年担任Mela Sciences，Inc.的首席执行官，并于2008年至2011年担任Epocrates，Inc.的首席执行官。她还曾在强生公司和百时美施贵宝公司担任过多个执行职位。她也曾担任Apple Tree Partners公司的商业化主管兼合伙人（从2011年到2013年）。Crane女士是Teva Pharmaceuticals Industries Ltd.和Cipher制药公司的董事会成员，也是纽约州立大学奥斯威戈商学院顾问委员会和纽约州立大学奥斯威戈分校基金会委员会成员。Crane女士拥有纽约州立大学奥斯威戈分校（State University of New York at Oswego）的通信学士学位和肯特州立大学（Kent State University）的工商管理硕士学位。
Rosemary Crane was elected to the board in April 2015 and has since acted as vice chairman and a member of the Audit Committee. She is an independent board member pursuant to the Danish Corporate Governance Recommendations. Ms. Crane served as CEO of MELA Sciences, Inc. from 2013 to 2014 and of Epocrates, Inc. from 2008 to 2011. She has also held a number of executive positions at Johnson & Johnson and Bristol-Myers Squibb Company. She also served as head of commercialization and a partner at Apple Tree Partners from 2011 to 2013. Ms. Crane is a member of the boards of Teva Pharmaceuticals Industries Ltd. and Cipher Pharmaceuticals Inc. and a member of the advisory boards of the State University of New York at Oswego School of Business and the foundation board of the State University of New York at Oswego. Ms. Crane holds a BA in communications from the State University of New York at Oswego and an MBA from Kent State University. - Rosemary Crane于2015年4月当选为董事会成员，此后一直担任副主席兼审计委员会成员。她是根据丹麦公司治理建议的独立董事会成员。Crane女士曾于2013年至2014年担任Mela Sciences，Inc.的首席执行官，并于2008年至2011年担任Epocrates，Inc.的首席执行官。她还曾在强生公司和百时美施贵宝公司担任过多个执行职位。她也曾担任Apple Tree Partners公司的商业化主管兼合伙人（从2011年到2013年）。Crane女士是Teva Pharmaceuticals Industries Ltd.和Cipher制药公司的董事会成员，也是纽约州立大学奥斯威戈商学院顾问委员会和纽约州立大学奥斯威戈分校基金会委员会成员。Crane女士拥有纽约州立大学奥斯威戈分校（State University of New York at Oswego）的通信学士学位和肯特州立大学（Kent State University）的工商管理硕士学位。
- Rosemary Crane was elected to the board in April 2015 and has since acted as vice chairman and a member of the Audit Committee. She is an independent board member pursuant to the Danish Corporate Governance Recommendations. Ms. Crane served as CEO of MELA Sciences, Inc. from 2013 to 2014 and of Epocrates, Inc. from 2008 to 2011. She has also held a number of executive positions at Johnson & Johnson and Bristol-Myers Squibb Company. She also served as head of commercialization and a partner at Apple Tree Partners from 2011 to 2013. Ms. Crane is a member of the boards of Teva Pharmaceuticals Industries Ltd. and Cipher Pharmaceuticals Inc. and a member of the advisory boards of the State University of New York at Oswego School of Business and the foundation board of the State University of New York at Oswego. Ms. Crane holds a BA in communications from the State University of New York at Oswego and an MBA from Kent State University.
- Catherine Moukheibir
-
Catherine Moukheibir，她一直担任Orphazyme A/S董事（2017年11月以来）。她目前担任MedDay Pharmaceuticals SA的董事会主席和首席执行官，以及Genkyotex SA、Ironwood Pharmaceuticals, Inc.和Kymab Ltd.的董事会成员。在此之前，她曾担任Innate Pharma SA的高级财务顾问和执行董事会成员（从2011年3月到2016年12月），并担任Movetis N.V。的首席财务官（从2008年到2010年，该公司被收购）。从2001年到2007年，她曾担任Zeltia Group S.A.的资本市场主管。除了在MedDay的董事会任职，她还在Orphazyme A/S、Genkyotex SA和Kymab Group Limited的董事会任职。她还曾担任Ablynx NV、Cerenis Therapeutics SA和Creabilis S.A.Ms的董事会董事。Moukheibir拥有耶鲁大学经济学硕士学位和工商管理硕士学位。
Catherine Moukheibir,most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chair of the board of directors of MedDay from April 2016 to January 2021.Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired.Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.Ms. Moukheibir currently serves on the board of directors of MoonLake Immunotherapeutics AG (Nasdaq: MLTX), a public company. Ms. Moukheibir also serves on the board of directors of Asceneuron SA, Esteve Healthcare, S.L., Noema Pharma AG and CMR Surgical, all of which are privately held companies. She held past directorships on the boards of directors of Ablynx NV, Biotalys NV, Cerenis Therapeutics SA, Creabilis S.A., DNA Script SAS, GenKyoTex S.A., Kymab Group Limited, Orphazyme A/S, Oxford Biomedica plc and Zealand Pharma A/S.Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University. - Catherine Moukheibir，她一直担任Orphazyme A/S董事（2017年11月以来）。她目前担任MedDay Pharmaceuticals SA的董事会主席和首席执行官，以及Genkyotex SA、Ironwood Pharmaceuticals, Inc.和Kymab Ltd.的董事会成员。在此之前，她曾担任Innate Pharma SA的高级财务顾问和执行董事会成员（从2011年3月到2016年12月），并担任Movetis N.V。的首席财务官（从2008年到2010年，该公司被收购）。从2001年到2007年，她曾担任Zeltia Group S.A.的资本市场主管。除了在MedDay的董事会任职，她还在Orphazyme A/S、Genkyotex SA和Kymab Group Limited的董事会任职。她还曾担任Ablynx NV、Cerenis Therapeutics SA和Creabilis S.A.Ms的董事会董事。Moukheibir拥有耶鲁大学经济学硕士学位和工商管理硕士学位。
- Catherine Moukheibir,most recently served as chief executive officer of MedDay Pharmaceuticals, or MedDay, a biopharmaceutical company that focused on nervous system disorders, from July 2019 to January 2021. She was also the chair of the board of directors of MedDay from April 2016 to January 2021.Prior to that, Ms. Moukheibir served as the senior advisor for finance and a member of the executive board of directors at Innate Pharma SA, an oncology company, from 2011 to 2016, and as the chief financial officer for Movetis N.V. from 2008 to 2010, when it was acquired.Ms. Moukheibir previously served as the director of capital markets for Zeltia Group S.A. from 2001 to 2007.Ms. Moukheibir currently serves on the board of directors of MoonLake Immunotherapeutics AG (Nasdaq: MLTX), a public company. Ms. Moukheibir also serves on the board of directors of Asceneuron SA, Esteve Healthcare, S.L., Noema Pharma AG and CMR Surgical, all of which are privately held companies. She held past directorships on the boards of directors of Ablynx NV, Biotalys NV, Cerenis Therapeutics SA, Creabilis S.A., DNA Script SAS, GenKyoTex S.A., Kymab Group Limited, Orphazyme A/S, Oxford Biomedica plc and Zealand Pharma A/S.Ms. Moukheibir has an M.A. in economics and an M.B.A. from Yale University.
- Michael J. Owen
-
MichaelJ.Owen自2012年4月起担任董事会成员。他是根据丹麦公司治理建议的独立董事会成员。Owen先生是Kymab Ltd.的联合创始人，并于2010年至2011年担任CSO。在加入Kymab之前，他曾在葛兰素史克制药有限公司担任多个领导职位，最近的职位是高级副总裁和生物制药研究主管。2001年加入葛兰素史克（GlaxoSmithKline）之前，他在帝国癌症研究基金（Imperial Cancer Research Fund）领导淋巴细胞分子生物学集团。他是the European Molecular Biology Organization的成员和the Academy of Medical Sciences的院士。Owen先生是Blink Biomedical SAS，Ossianix，Inc.，Avacta Group plc，Gammadelta Therapeutics Limited，Reneuron plc和Glythera Limited的董事会成员。Owen先生也是CRT Pioneer Fund LP的顾问。Owen先生拥有牛津大学（Oxford University）生物化学学士学位和剑桥大学（Cambridge University）生物化学博士学位。
Michael J. Owen has been member of the board since April 2012. He is an independent board member pursuant to the Danish Corporate Governance Recommendations. Mr. Owen is a co-founder and was CSO at Kymab Ltd. from 2010 to 2011. Before joining Kymab, he had several leading positions at GlaxoSmithKline Pharmaceuticals Ltd. most recently as Senior Vice President and head of biopharmaceuticals research. Prior to joining GlaxoSmithKline in 2001 he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He is a member of the European Molecular Biology Organization and Fellowship of the Academy of Medical Sciences. Mr. Owen is a member of the boards of BliNK Biomedical SAS, Ossianix, Inc., Avacta Group plc, GammaDelta Therapeutics Limited, ReNeuron plc and Glythera Limited. Mr. Owen is also an advisor to CRT Pioneer Fund LP. Mr. Owen holds a BA in Biochemistry from Oxford University and a PhD in biochemistry from Cambridge University. - MichaelJ.Owen自2012年4月起担任董事会成员。他是根据丹麦公司治理建议的独立董事会成员。Owen先生是Kymab Ltd.的联合创始人，并于2010年至2011年担任CSO。在加入Kymab之前，他曾在葛兰素史克制药有限公司担任多个领导职位，最近的职位是高级副总裁和生物制药研究主管。2001年加入葛兰素史克（GlaxoSmithKline）之前，他在帝国癌症研究基金（Imperial Cancer Research Fund）领导淋巴细胞分子生物学集团。他是the European Molecular Biology Organization的成员和the Academy of Medical Sciences的院士。Owen先生是Blink Biomedical SAS，Ossianix，Inc.，Avacta Group plc，Gammadelta Therapeutics Limited，Reneuron plc和Glythera Limited的董事会成员。Owen先生也是CRT Pioneer Fund LP的顾问。Owen先生拥有牛津大学（Oxford University）生物化学学士学位和剑桥大学（Cambridge University）生物化学博士学位。
- Michael J. Owen has been member of the board since April 2012. He is an independent board member pursuant to the Danish Corporate Governance Recommendations. Mr. Owen is a co-founder and was CSO at Kymab Ltd. from 2010 to 2011. Before joining Kymab, he had several leading positions at GlaxoSmithKline Pharmaceuticals Ltd. most recently as Senior Vice President and head of biopharmaceuticals research. Prior to joining GlaxoSmithKline in 2001 he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He is a member of the European Molecular Biology Organization and Fellowship of the Academy of Medical Sciences. Mr. Owen is a member of the boards of BliNK Biomedical SAS, Ossianix, Inc., Avacta Group plc, GammaDelta Therapeutics Limited, ReNeuron plc and Glythera Limited. Mr. Owen is also an advisor to CRT Pioneer Fund LP. Mr. Owen holds a BA in Biochemistry from Oxford University and a PhD in biochemistry from Cambridge University.
- Hanne Heidenheim Bak
-
Hanne Heidenheim Bak是2016年初加入董事会的民选员工，此前曾于2012年至2014年担任董事会成员。Bak女士担任高级项目总监和研发运营经理。在2006年加入我们之前，Bak女士在Lundbeck A/S担任了8年的后期开发项目经理，随后在H.Lundbeck Institute担任了9年的执行董事。Bak女士是Pharma Guidance APS的执行董事。她持有the Danish University of Pharmaceutical Sciences的药学硕士学位。
Hanne Heidenheim Bak is an employee elected member who joined the board in early 2016 after previously serving on the board in this capacity from 2012 to 2014. Ms. Bak serves as Senior Project Director and R&D Operations Manager. Prior to joining us in 2006 Ms. Bak worked for eight years as Project Manager of late-phase development programs at Lundbeck A/S, followed by nine years as executive director at the H. Lundbeck Institute. Ms. Bak is an executive director of PHARMA GUIDANCE ApS. She holds a MS in Pharmacy from the Danish University of Pharmaceutical Sciences. - Hanne Heidenheim Bak是2016年初加入董事会的民选员工，此前曾于2012年至2014年担任董事会成员。Bak女士担任高级项目总监和研发运营经理。在2006年加入我们之前，Bak女士在Lundbeck A/S担任了8年的后期开发项目经理，随后在H.Lundbeck Institute担任了9年的执行董事。Bak女士是Pharma Guidance APS的执行董事。她持有the Danish University of Pharmaceutical Sciences的药学硕士学位。
- Hanne Heidenheim Bak is an employee elected member who joined the board in early 2016 after previously serving on the board in this capacity from 2012 to 2014. Ms. Bak serves as Senior Project Director and R&D Operations Manager. Prior to joining us in 2006 Ms. Bak worked for eight years as Project Manager of late-phase development programs at Lundbeck A/S, followed by nine years as executive director at the H. Lundbeck Institute. Ms. Bak is an executive director of PHARMA GUIDANCE ApS. She holds a MS in Pharmacy from the Danish University of Pharmaceutical Sciences.
- Rasmus Just
-
Rasmus Just生于1976年，丹麦国籍，是2016年初加入董事会的民选雇员。Just博士于2003年加入我们，并担任Boehringer Ingelheim Collaboration的首席科学家，心脏代谢创新主管和国际合作项目负责人。2016年，Just博士被提升为业务开发和创新采购总监。Just博士是VJack Holding IVS的执行董事，之前是Sea Longevity APS和Vitaminpack IVS的执行董事。Just博士拥有哥本哈根大学（University of Copenhagen）的生物学硕士学位，AVT商学院（哥本哈根）的执行工商管理硕士学位和哥本哈根大学（University of Copenhagen）的分子药理学博士学位。
Rasmus Just born 1976 Danish nationality is an employee elected member who joined the board in early 2016. Dr. Just joined us in 2003 and has held positions as Principal Scientist, Head of Cardiometabolic Innovation, and as International Collaboration Project Leader for the Boehringer Ingelheim collaboration. In 2016 Dr. Just was promoted to Director of Business Development and Innovation Sourcing. Dr. Just is an executive director of Vjack Holding IVS and was previously executive director of Sea Longevity ApS and Vitaminpack IVS. Dr. Just holds an MS in Biology from the University of Copenhagen, an executive MBA from AVT Business School (Copenhagen) and a PhD in Molecular Pharmacology from University of Copenhagen. - Rasmus Just生于1976年，丹麦国籍，是2016年初加入董事会的民选雇员。Just博士于2003年加入我们，并担任Boehringer Ingelheim Collaboration的首席科学家，心脏代谢创新主管和国际合作项目负责人。2016年，Just博士被提升为业务开发和创新采购总监。Just博士是VJack Holding IVS的执行董事，之前是Sea Longevity APS和Vitaminpack IVS的执行董事。Just博士拥有哥本哈根大学（University of Copenhagen）的生物学硕士学位，AVT商学院（哥本哈根）的执行工商管理硕士学位和哥本哈根大学（University of Copenhagen）的分子药理学博士学位。
- Rasmus Just born 1976 Danish nationality is an employee elected member who joined the board in early 2016. Dr. Just joined us in 2003 and has held positions as Principal Scientist, Head of Cardiometabolic Innovation, and as International Collaboration Project Leader for the Boehringer Ingelheim collaboration. In 2016 Dr. Just was promoted to Director of Business Development and Innovation Sourcing. Dr. Just is an executive director of Vjack Holding IVS and was previously executive director of Sea Longevity ApS and Vitaminpack IVS. Dr. Just holds an MS in Biology from the University of Copenhagen, an executive MBA from AVT Business School (Copenhagen) and a PhD in Molecular Pharmacology from University of Copenhagen.
- Jens Peter Stenvang
-
Jens Peter Stenvang自2014年以来一直是董事会当选成员。Stenvang先生受雇于我们，担任应用程序专员。在2010年10月加入我们之前，Stenvang先生曾在Dako A/S和Beckman Coulter Inc.担任全球流式细胞术支持。Stenvang先生从1990年代初开始担任丹麦流式细胞术学会（Danish Society for Flow Cyctometry）的董事会成员，不包括2010年至2012年期间。他持有生物学实验室技术员学位，曾在领先大学从事癌症和糖尿病研究，包括加州大学伯克利分校（the University of California at Berkeley）。
Jens Peter Stenvang has been an employee elected member of the board since 2014. Mr. Stenvang is employed by us as application specialist. Before joining us in October 2010 Mr. Stenvang worked for Dako A/S and Beckman Coulter Inc. as global flow cytometry support. Mr. Stenvang has served as a member of the board of the Danish Society for Flow Cytometry since the early 1990s, excluding the period from 2010 to 2012. He holds a Laboratory Technician degree in Biology and has worked with cancer and diabetes research at leading universities, including the University of California at Berkeley. - Jens Peter Stenvang自2014年以来一直是董事会当选成员。Stenvang先生受雇于我们，担任应用程序专员。在2010年10月加入我们之前，Stenvang先生曾在Dako A/S和Beckman Coulter Inc.担任全球流式细胞术支持。Stenvang先生从1990年代初开始担任丹麦流式细胞术学会（Danish Society for Flow Cyctometry）的董事会成员，不包括2010年至2012年期间。他持有生物学实验室技术员学位，曾在领先大学从事癌症和糖尿病研究，包括加州大学伯克利分校（the University of California at Berkeley）。
- Jens Peter Stenvang has been an employee elected member of the board since 2014. Mr. Stenvang is employed by us as application specialist. Before joining us in October 2010 Mr. Stenvang worked for Dako A/S and Beckman Coulter Inc. as global flow cytometry support. Mr. Stenvang has served as a member of the board of the Danish Society for Flow Cytometry since the early 1990s, excluding the period from 2010 to 2012. He holds a Laboratory Technician degree in Biology and has worked with cancer and diabetes research at leading universities, including the University of California at Berkeley.
- Martin Nicklasson
-
Martin Nicklasson， 他是Nicklasson Life Science 公司（一个独立的咨询公司，制药和生物技术行业的咨询公司）的高级合伙人（自2011年以来）。他曾担任Biovitrum公司和Swedish Orphan Biovitrum公司（一个公开上市的专业制药公司）的总裁兼行政总裁（从2007年到2010年）。他曾担任AstraZeneca公司的多种执行副总裁的职位（从1999年到2007年），包括 Astra Tech公司（AstraZeneca公司的子公司）的董事会主席（从2004年到2007年）、负责全球营销和业务发展的执行副总裁（从2005年到2007年）、负责全球药物研发的执行副总裁（从2002年到2005年）和负责全球肠胃特许经营执行副总裁（从1999年到2002年）。他担任Farma Holdings公司和Orexo公司的董事会主席， 并任职于Oasmia AB、Denator AB、Biocrine AB和Heart and Lung Foundation of Sweden的董事会。
Martin Nicklasson, senior Partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector since 2011. President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB, a publicly listed specialty pharma company, from 2007 to 2010. Held various executive vice president positions at AstraZeneca Plc. from 1999 to 2007 including Chairman of the Board of Astra Tech AB, a subsidiary of AstraZeneca from 2004 to 2007 Executive Vice President, Global Marketing & Business Development (from 2005 to 2007), Executive Vice President, Global Drug Development (from 2002 to 2005) and Executive Vice President, Global Gastrointestinal Franchise (from 1999 to 2002). Serves as Chairman of the Board of Farma Holdings AS and Orexo AB and serves on the Board of Oasmia AB, Denator AB, Biocrine AB and Heart and Lung Foundation of Sweden. - Martin Nicklasson， 他是Nicklasson Life Science 公司（一个独立的咨询公司，制药和生物技术行业的咨询公司）的高级合伙人（自2011年以来）。他曾担任Biovitrum公司和Swedish Orphan Biovitrum公司（一个公开上市的专业制药公司）的总裁兼行政总裁（从2007年到2010年）。他曾担任AstraZeneca公司的多种执行副总裁的职位（从1999年到2007年），包括 Astra Tech公司（AstraZeneca公司的子公司）的董事会主席（从2004年到2007年）、负责全球营销和业务发展的执行副总裁（从2005年到2007年）、负责全球药物研发的执行副总裁（从2002年到2005年）和负责全球肠胃特许经营执行副总裁（从1999年到2002年）。他担任Farma Holdings公司和Orexo公司的董事会主席， 并任职于Oasmia AB、Denator AB、Biocrine AB和Heart and Lung Foundation of Sweden的董事会。
- Martin Nicklasson, senior Partner at Nicklasson Life Science AB, an independent consultancy and advisory company to the pharmaceutical and biotechnology sector since 2011. President and Chief Executive Officer of Biovitrum AB and Swedish Orphan Biovitrum AB, a publicly listed specialty pharma company, from 2007 to 2010. Held various executive vice president positions at AstraZeneca Plc. from 1999 to 2007 including Chairman of the Board of Astra Tech AB, a subsidiary of AstraZeneca from 2004 to 2007 Executive Vice President, Global Marketing & Business Development (from 2005 to 2007), Executive Vice President, Global Drug Development (from 2002 to 2005) and Executive Vice President, Global Gastrointestinal Franchise (from 1999 to 2002). Serves as Chairman of the Board of Farma Holdings AS and Orexo AB and serves on the Board of Oasmia AB, Denator AB, Biocrine AB and Heart and Lung Foundation of Sweden.
高管简历
中英对照 | 中文 | 英文- Mats Blom
Mats Blom自2017年4月以来一直是我们的董事会成员。Blom先生是Northsea Therapeutics B.V.的首席财务官首席财务官，该公司是一家专注于口服、结构工程脂质疗法的生物技术公司。加入Northsea公司之前，他曾担任Modus Therapeutics A/B公司（生物技术公司，开发治疗药物以恢复衰弱疾病患者的健康血流）、Zealand Pharma A/B公司（生物技术公司，专注于创新肽类药物的发现、设计和开发）、Swedish Orphan International公司的首席财务官，2009年被BioVitrum收购的孤儿药公司。此外，Blom先生拥有丰富的管理经验，曾在Active Biotech AB和Anoto Group AB担任首席财务官职位。此前，他曾担任Gemini Consulting公司、Ernst&Young公司的管理顾问。Mats Blom拥有隆德大学工商管理和经济学学士学位和巴塞罗那IESE纳瓦拉大学工商管理硕士学位。
Mats Blom has been a member of our Board of Directors since April 2017. Mr. Blom is Chief Financial Officer CFO of NorthSea Therapeutics B.V., a biotechnology company focused on oral, structurally-engineered lipid therapeutics. Prior to joining NorthSea, he served as CFO of Modus Therapeutics A/B, a biotechnology company developing therapeutics to restore healthy blood flow for patients with debilitating diseases, Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mr. Blom has extensive managerial experience and has held CFO positions at Active Biotech AB and Anoto Group AB. Previously, he served as a management consultant at Gemini Consulting and Ernst & Young. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.- Mats Blom自2017年4月以来一直是我们的董事会成员。Blom先生是Northsea Therapeutics B.V.的首席财务官首席财务官，该公司是一家专注于口服、结构工程脂质疗法的生物技术公司。加入Northsea公司之前，他曾担任Modus Therapeutics A/B公司（生物技术公司，开发治疗药物以恢复衰弱疾病患者的健康血流）、Zealand Pharma A/B公司（生物技术公司，专注于创新肽类药物的发现、设计和开发）、Swedish Orphan International公司的首席财务官，2009年被BioVitrum收购的孤儿药公司。此外，Blom先生拥有丰富的管理经验，曾在Active Biotech AB和Anoto Group AB担任首席财务官职位。此前，他曾担任Gemini Consulting公司、Ernst&Young公司的管理顾问。Mats Blom拥有隆德大学工商管理和经济学学士学位和巴塞罗那IESE纳瓦拉大学工商管理硕士学位。
- Mats Blom has been a member of our Board of Directors since April 2017. Mr. Blom is Chief Financial Officer CFO of NorthSea Therapeutics B.V., a biotechnology company focused on oral, structurally-engineered lipid therapeutics. Prior to joining NorthSea, he served as CFO of Modus Therapeutics A/B, a biotechnology company developing therapeutics to restore healthy blood flow for patients with debilitating diseases, Zealand Pharma A/B, a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines, and Swedish Orphan International, an orphan drug company acquired by BioVitrum in 2009. In addition, Mr. Blom has extensive managerial experience and has held CFO positions at Active Biotech AB and Anoto Group AB. Previously, he served as a management consultant at Gemini Consulting and Ernst & Young. Mats Blom holds a BA in Business Administration and Economics from the University of Lund and an MBA from IESE University of Navarra, Barcelona.
- Adam Steensberg
Adam Steensberg于2010年加入我们，担任首席医疗和发展官。自2011年以来，Steensberg先生一直领导所有开发活动，并于2015年晋升为高级副总裁兼首席医疗和开发官。Steensberg先生于2017年5月晋升为执行Vice President。在加入我们之前，Steensberg先生作为Novo NordiskA/S的医学主任领导了几个临床研究小组，他有在哥本哈根大学医院担任临床医生的经验。Steensberg先生曾担任内分泌学，心脏病学，胃肠病学和风湿病学的医疗和科学顾问。Steensberg先生拥有IMD Switzerland的工商管理硕士学位和University of Copenhagen的医学博士和DMS。
Adam Steensberg joined us as Chief Medical and Development Officer in 2010. Since 2011 Mr. Steensberg has lead all development activities and was promoted to Senior Vice President and Chief Medical and Development Officer in 2015. Mr. Steensberg was promoted to Executive Vice President in May 2017. Prior to joining us, Mr. Steensberg led several clinical research teams as Medical Director at Novo Nordisk A/S, and he has experience as a clinician in the University Hospital of Copenhagen. Mr. Steensberg has served as Medical and Scientific Advisor within endocrinology, cardiology,gastroenterology and rheumatology. Mr. Steensberg holds an MBA from IMD Switzerland and an MD and a DMS from the University of Copenhagen.- Adam Steensberg于2010年加入我们，担任首席医疗和发展官。自2011年以来，Steensberg先生一直领导所有开发活动，并于2015年晋升为高级副总裁兼首席医疗和开发官。Steensberg先生于2017年5月晋升为执行Vice President。在加入我们之前，Steensberg先生作为Novo NordiskA/S的医学主任领导了几个临床研究小组，他有在哥本哈根大学医院担任临床医生的经验。Steensberg先生曾担任内分泌学，心脏病学，胃肠病学和风湿病学的医疗和科学顾问。Steensberg先生拥有IMD Switzerland的工商管理硕士学位和University of Copenhagen的医学博士和DMS。
- Adam Steensberg joined us as Chief Medical and Development Officer in 2010. Since 2011 Mr. Steensberg has lead all development activities and was promoted to Senior Vice President and Chief Medical and Development Officer in 2015. Mr. Steensberg was promoted to Executive Vice President in May 2017. Prior to joining us, Mr. Steensberg led several clinical research teams as Medical Director at Novo Nordisk A/S, and he has experience as a clinician in the University Hospital of Copenhagen. Mr. Steensberg has served as Medical and Scientific Advisor within endocrinology, cardiology,gastroenterology and rheumatology. Mr. Steensberg holds an MBA from IMD Switzerland and an MD and a DMS from the University of Copenhagen.
- Andrew Parker
Andrew Parker于2016年7月加入我们，担任高级副总裁，首席科学官。帕克博士于2017年5月晋升为执行Vice President。在加入我们之前，Parker博士于2016年1月至6月担任Eclosion SA的普通合伙人兼科学总监，并于同一时期担任Arisgen SA（一家Eclosion投资组合公司）的首席执行官。Parker博士自2016年7月起担任Eclosion SA的董事会成员。此前，帕克博士曾于2011年1月至2013年12月担任Shire plc的Vice President兼勘探项目主管。Parker博士此前曾担任Dengen SA和Genneuro SA的董事会成员。Parker博士拥有萨里大学（University of Surrey）的学士学位（荣誉），国家医学研究所（National Institute for Medical Research）的博士学位和华威大学商学院（Warwick University Business School）的工商管理硕士学位。
Andrew Parker joined us in July 2016 as Senior Vice President, Chief Science Officer. Dr. Parker was promoted to Executive Vice President in May 2017. Prior to joining us, Dr. Parker served as General Partner and Scientific Director at Eclosion SA from January to June 2016 and CEO of Arisgen SA an Eclosion portfolio company during that same time period. Dr. Parker has served as a member of Eclosion SA's board of directors since July 2016. Previously, Dr. Parker worked as Vice President and Head of Exploratory Projects for Shire plc from January 2011 to December 2013. Dr. Parker previously served as a board member of DenGen SA and GenNeuro SA. Dr. Parker holds a B.Sc (Hons) from the University of Surrey, a Ph.D. from the National Institute for Medical Research and an MBA from Warwick University Business School.- Andrew Parker于2016年7月加入我们，担任高级副总裁，首席科学官。帕克博士于2017年5月晋升为执行Vice President。在加入我们之前，Parker博士于2016年1月至6月担任Eclosion SA的普通合伙人兼科学总监，并于同一时期担任Arisgen SA（一家Eclosion投资组合公司）的首席执行官。Parker博士自2016年7月起担任Eclosion SA的董事会成员。此前，帕克博士曾于2011年1月至2013年12月担任Shire plc的Vice President兼勘探项目主管。Parker博士此前曾担任Dengen SA和Genneuro SA的董事会成员。Parker博士拥有萨里大学（University of Surrey）的学士学位（荣誉），国家医学研究所（National Institute for Medical Research）的博士学位和华威大学商学院（Warwick University Business School）的工商管理硕士学位。
- Andrew Parker joined us in July 2016 as Senior Vice President, Chief Science Officer. Dr. Parker was promoted to Executive Vice President in May 2017. Prior to joining us, Dr. Parker served as General Partner and Scientific Director at Eclosion SA from January to June 2016 and CEO of Arisgen SA an Eclosion portfolio company during that same time period. Dr. Parker has served as a member of Eclosion SA's board of directors since July 2016. Previously, Dr. Parker worked as Vice President and Head of Exploratory Projects for Shire plc from January 2011 to December 2013. Dr. Parker previously served as a board member of DenGen SA and GenNeuro SA. Dr. Parker holds a B.Sc (Hons) from the University of Surrey, a Ph.D. from the National Institute for Medical Research and an MBA from Warwick University Business School.